Healthcare
Bright Minds Biosciences Inc.(DRUG)
Live Price
Offline$60.66
+1.92% today
1Y Change
+132.32%
Window
Jun 30, 2025 โ Jun 18, 2026
- Market Cap
- $890.00M
- Revenue Growth
- 0.0%
- EPS Growth
- -173.8%
- Dividend Yield
- 0.0%
Coverage: 244 bars ยท Jun 30, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Bright Minds Biosciences Inc. (DRUG) is a Healthcare stock with a market cap of $890.00M and listed on NASDAQ. The stock last traded around $60.66 and up 132.3% across the available one-year price window (Jun 30, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -173.8%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -173.8%, free cash flow -369.8% with operating margin 0.0% and ROIC -21.5%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines DRUG price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 15, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -173.8%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +4.3% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 15, 2026 | โ | -3.2% | +7.8% | -23.6% |
2026 Feb 12, 2026 | +28.6% | -3.3% | +6.1% | -10.6% |
2025 Dec 23, 2025 | +27.1% | +0.5% | -1.0% | +2.2% |
Benchmark Edge
DRUG vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
Relative Read
Mixed setup vs SPY
DRUG is 111.46 pts ahead over the shared 1Y window.
DRUG had 29.22 pts deeper max drawdown than SPY.
DRUG beat SPY in 1 of 2 calendar years shown and trailed in 1.
DRUG
+132.32%
Normalized return
SPY
+20.86%
S&P 500
Excess Return
+111.46 pts
Relative to SPY
DRUG Max Drawdown
-38.35%
Trailing 1Y
SPY Max Drawdown
-9.13%
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for DRUG and SPY.
| Year | DRUG | SPY | Excess | Leader |
|---|---|---|---|---|
| 2026 | -27.32% | +6.71% | -34.03 pts | SPY |
| 2025 | +190.50% | +11.19% | +179.31 pts | DRUG |
Company Overview
Bright Minds Biosciences Inc.
NASDAQ Capital Market
Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.
- Leadership
- Ian McDonald
- IPO Date
- Mar 22, 2021
- Employees
- 26
- Street Address
- 1500 โ 1055 West Georgia Street
- Mailing
- New York City, BC, V6E 4N7
- Region
- New York City, BC, CA
- Reporting Currency
- USD
- Investor Line
- 647 407 2515
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 10.0
Growth
- Revenue
- 0.0%
- EPS
- -173.8%
- Free Cash Flow
- -369.8%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -28.5%
- ROIC
- -21.5%
Balance Sheet
- Debt/Equity
- 0.00
- Current Ratio
- 57.37
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.